{
    "posts": [
      {
        "thread": {
          "uuid": "110b23cb3bdf6d0f0fcb3a4bec10c012931bf820",
          "url": "https://www.americanbankingnews.com/2020/03/22/marshall-wace-llp-lowers-position-in-emergent-biosolutions-inc-nyseebs.html",
          "site_full": "www.americanbankingnews.com",
          "site": "americanbankingnews.com",
          "site_section": "http://feeds.feedburner.com/AmericanBankingNews",
          "site_categories": [
            "financial_news",
            "finance"
          ],
          "section_title": "American Banking News",
          "title": "Marshall Wace LLP Lowers Position in Emergent Biosolutions Inc (NYSE:EBS)",
          "title_full": "Marshall Wace LLP Lowers Position in Emergent Biosolutions Inc (NYSE:EBS)",
          "published": "2020-03-22T16:16:00.000+02:00",
          "replies_count": 0,
          "participants_count": 1,
          "site_type": "news",
          "country": "US",
          "spam_score": 0.0,
          "main_image": "https://www.marketbeat.com/logos/emergent-biosolutions-inc-logo.jpg",
          "performance_score": 0,
          "domain_rank": null,
          "social": {
            "facebook": {
              "likes": 0,
              "comments": 0,
              "shares": 0
            },
            "gplus": {
              "shares": 0
            },
            "pinterest": {
              "shares": 0
            },
            "linkedin": {
              "shares": 0
            },
            "stumbledupon": {
              "shares": 0
            },
            "vk": {
              "shares": 0
            }
          }
        },
        "uuid": "110b23cb3bdf6d0f0fcb3a4bec10c012931bf820",
        "url": "https://www.americanbankingnews.com/2020/03/22/marshall-wace-llp-lowers-position-in-emergent-biosolutions-inc-nyseebs.html",
        "ord_in_thread": 0,
        "parent_url": null,
        "author": "ABMN Staff",
        "published": "2020-03-22T16:16:00.000+02:00",
        "title": "Marshall Wace LLP Lowers Position in Emergent Biosolutions Inc (NYSE:EBS)",
        "text": "Marshall Wace LLP trimmed its stake in Emergent Biosolutions Inc (NYSE:EBS) by 44.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 163,975 shares of the biopharmaceutical company’s stock after selling 130,267 shares during the quarter. Marshall Wace LLP owned about 0.32% of Emergent Biosolutions worth $8,846,000 as of its most recent filing with the SEC.\nOther institutional investors also recently added to or reduced their stakes in the company. Municipal Employees Retirement System of Michigan grew its stake in Emergent Biosolutions by 2.0% during the fourth quarter. Municipal Employees Retirement System of Michigan now owns 13,420 shares of the biopharmaceutical company’s stock worth $724,000 after buying an additional 260 shares during the period. Comerica Bank grew its stake in Emergent Biosolutions by 0.7% during the fourth quarter. Comerica Bank now owns 42,045 shares of the biopharmaceutical company’s stock worth $2,320,000 after buying an additional 288 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Emergent Biosolutions by 11.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,888 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 294 shares during the period. SG Americas Securities LLC grew its stake in Emergent Biosolutions by 17.5% during the third quarter. SG Americas Securities LLC now owns 3,612 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 538 shares during the period. Finally, Aigen Investment Management LP purchased a new stake in Emergent Biosolutions during the fourth quarter worth approximately $32,000. Hedge funds and other institutional investors own 86.69% of the company’s stock. Get Emergent Biosolutions alerts:\nSeveral research firms have issued reports on EBS. Cowen began coverage on shares of Emergent Biosolutions in a research note on Thursday, March 12th. They set a “hold” rating and a $67.00 price objective for the company. Wells Fargo & Co boosted their price objective on shares of Emergent Biosolutions from $66.00 to $75.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $70.83.\nShares of EBS stock opened at $49.34 on Friday. The company has a market capitalization of $2.76 billion, a PE ratio of 47.90 and a beta of 1.32. The firm has a fifty day simple moving average of $60.13 and a 200-day simple moving average of $55.65. The company has a current ratio of 3.17, a quick ratio of 2.14 and a debt-to-equity ratio of 0.73. Emergent Biosolutions Inc has a twelve month low of $39.11 and a twelve month high of $71.19.\nEmergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.67 by ($0.10). The firm had revenue of $360.40 million during the quarter, compared to analysts’ expectations of $357.18 million. Emergent Biosolutions had a net margin of 4.94% and a return on equity of 14.19%. Emergent Biosolutions’s revenue for the quarter was up 33.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.75 earnings per share. Equities research analysts predict that Emergent Biosolutions Inc will post 3.43 EPS for the current year.\nIn related news, Director Zsolt Harsanyi sold 3,435 shares of the company’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $55.00, for a total value of $188,925.00. Following the sale, the director now directly owns 36,273 shares of the company’s stock, valued at $1,995,015. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink . Also, Director Kathryn C. Zoon sold 991 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $60.65, for a total transaction of $60,104.15. Following the completion of the sale, the director now directly owns 16,421 shares in the company, valued at $995,933.65. The disclosure for this sale can be found here . Insiders sold 111,232 shares of company stock valued at $6,844,641 over the last 90 days. Insiders own 14.10% of the company’s stock.\nEmergent Biosolutions Company Profile\nEmergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.\nRead More: Why are gap-down stocks important?\nWant to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS). Receive News & Ratings for Emergent Biosolutions analysts' ratings for Emergent Biosolutions and related companies daily email newsletter . «",
        "highlightText": "",
        "highlightTitle": "",
        "language": "english",
        "external_links": [
          "https://sec.gov/Archives/edgar/data/1193522/000136764420000025/xslF345X03/wf-form4_158353064805074.xml",
          "https://www.sec.gov/Archives/edgar/data/1367644/000136764420000004/xslF345X03/wf-form4_157929595097570.xml",
          "https://sec.gov/Archives/edgar/data/1367644/000136764420000004/xslF345X03/wf-form4_157929595097570.xml",
          "https://marketbeat.com/market-data/gap-down-stocks/",
          "https://www.marketbeat.com/stocks/NYSE/EBS/sec-filings",
          "https://marketbeat.com/newsletter/default.aspx",
          "https://www.marketbeat.com/stocks/NYSE/EBS/sec-filings/",
          "https://www.holdingschannel.com/hedge-funds/holding-ebs",
          "https://www.marketbeat.com/market-data/gap-down-stocks/",
          "https://www.marketbeat.com/market-data/gap-down-stocks",
          "https://marketbeat.com/stocks/NYSE/EBS/sec-filings/",
          "https://www.holdingschannel.com/hedge-funds/holding-ebs/",
          "https://holdingschannel.com/hedge-funds/holding-ebs/",
          "https://www.marketbeat.com/newsletter/default.aspx",
          "https://www.sec.gov/Archives/edgar/data/1193522/000136764420000025/xslF345X03/wf-form4_158353064805074.xml"
        ],
        "external_images": null,
        "entities": {
          "persons": [
            {
              "name": "zurcher kantonalbank zurich cantonalb",
              "sentiment": "none"
            }
          ],
          "organizations": [
            {
              "name": "marshall wace llp lowers position in emergent biosolutions inc",
              "sentiment": "none"
            },
            {
              "name": "marshall wace llp",
              "sentiment": "none"
            },
            {
              "name": "emergent biosolutions inc",
              "sentiment": "none"
            },
            {
              "name": "sec",
              "sentiment": "none"
            },
            {
              "name": "comerica bank",
              "sentiment": "none"
            }
          ],
          "locations": [
            {
              "name": "michigan",
              "sentiment": "none"
            }
          ]
        },
        "rating": null,
        "crawled": "2020-03-22T17:07:36.013+02:00"
      },
      {
        "thread": {
          "uuid": "a57642462e92e8b19172b204ddd15393ad9d117b",
          "url": "https://www.americanbankingnews.com/2020/03/22/marshall-wace-llp-purchases-shares-of-420765-adient-plc-nyseadnt.html",
          "site_full": "www.americanbankingnews.com",
          "site": "americanbankingnews.com",
          "site_section": "http://feeds.feedburner.com/AmericanBankingNews",
          "site_categories": [
            "financial_news",
            "finance"
          ],
          "section_title": "American Banking News",
          "title": "Marshall Wace LLP Purchases Shares of 420,765 Adient PLC (NYSE:ADNT)",
          "title_full": "Marshall Wace LLP Purchases Shares of 420,765 Adient PLC (NYSE:ADNT)",
          "published": "2020-03-22T16:16:00.000+02:00",
          "replies_count": 0,
          "participants_count": 1,
          "site_type": "news",
          "country": "US",
          "spam_score": 0.0,
          "main_image": "https://www.marketbeat.com/logos/adient-logo.jpg",
          "performance_score": 0,
          "domain_rank": null,
          "social": {
            "facebook": {
              "likes": 0,
              "comments": 0,
              "shares": 0
            },
            "gplus": {
              "shares": 0
            },
            "pinterest": {
              "shares": 0
            },
            "linkedin": {
              "shares": 0
            },
            "stumbledupon": {
              "shares": 0
            },
            "vk": {
              "shares": 0
            }
          }
        },
        "uuid": "a57642462e92e8b19172b204ddd15393ad9d117b",
        "url": "https://www.americanbankingnews.com/2020/03/22/marshall-wace-llp-purchases-shares-of-420765-adient-plc-nyseadnt.html",
        "ord_in_thread": 0,
        "parent_url": null,
        "author": "ABMN Staff",
        "published": "2020-03-22T16:16:00.000+02:00",
        "title": "Marshall Wace LLP Purchases Shares of 420,765 Adient PLC (NYSE:ADNT)",
        "text": "Marshall Wace LLP purchased a new stake in Adient PLC (NYSE:ADNT) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 420,765 shares of the company’s stock, valued at approximately $8,941,000. Marshall Wace LLP owned about 0.45% of Adient as of its most recent filing with the Securities and Exchange Commission (SEC).\nA number of other large investors have also bought and sold shares of ADNT. CWM LLC boosted its holdings in Adient by 629.2% in the fourth quarter. CWM LLC now owns 1,597 shares of the company’s stock valued at $34,000 after purchasing an additional 1,378 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Adient by 92.0% in the third quarter. Tower Research Capital LLC TRC now owns 2,553 shares of the company’s stock valued at $59,000 after purchasing an additional 1,223 shares during the last quarter. Pendal Group Ltd purchased a new stake in Adient in the fourth quarter valued at $77,000. DekaBank Deutsche Girozentrale purchased a new stake in Adient in the fourth quarter valued at $104,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Adient by 14.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,794 shares of the company’s stock valued at $123,000 after purchasing an additional 710 shares during the last quarter. 96.91% of the stock is currently owned by institutional investors. Get Adient alerts:\nIn related news, VP Jerome J. Dorlack purchased 2,700 shares of Adient stock in a transaction that occurred on Friday, March 13th. The stock was purchased at an average price of $13.11 per share, for a total transaction of $35,397.00. Following the transaction, the vice president now directly owns 93,973 shares in the company, valued at $1,231,986.03. The acquisition was disclosed in a document filed with the SEC, which is available at this link . Also, CFO Jeffrey Stafeil purchased 5,858 shares of Adient stock in a transaction that occurred on Tuesday, March 10th. The shares were bought at an average price of $17.07 per share, with a total value of $99,996.06. Following the transaction, the chief financial officer now owns 130,371 shares in the company, valued at $2,225,432.97. The disclosure for this purchase can be found here . In the last 90 days, insiders have purchased 8,923 shares of company stock valued at $140,419. Insiders own 0.21% of the company’s stock.\nShares of Adient stock opened at $8.61 on Friday. The firm has a 50-day simple moving average of $22.40 and a two-hundred day simple moving average of $22.16. The company has a market cap of $797.24 million, a P/E ratio of -1.26, a price-to-earnings-growth ratio of 0.14 and a beta of 2.69. Adient PLC has a fifty-two week low of $5.90 and a fifty-two week high of $29.27. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.82 and a current ratio of 1.03.\nAdient (NYSE:ADNT) last released its quarterly earnings results on Friday, January 31st. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.65. Adient had a negative net margin of 3.93% and a positive return on equity of 9.32%. The firm had revenue of $3.94 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter in the prior year, the firm earned $0.31 EPS. The company’s revenue for the quarter was down 5.3% on a year-over-year basis. Equities research analysts forecast that Adient PLC will post 1.14 EPS for the current year.\nA number of brokerages have weighed in on ADNT. Credit Suisse Group upgraded shares of Adient from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $22.00 to $26.00 in a research report on Monday, January 27th. Morgan Stanley decreased their price objective on shares of Adient from $27.00 to $12.00 and set an “equal weight” rating for the company in a research report on Monday, March 16th. Buckingham Research upgraded shares of Adient from an “underperform” rating to a “neutral” rating and upped their price objective for the stock from $20.00 to $27.00 in a research report on Monday, February 3rd. Benchmark began coverage on shares of Adient in a research report on Thursday, January 9th. They issued a “hold” rating for the company. Finally, Bank of America upgraded shares of Adient from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $24.00 to $28.00 in a research report on Friday, January 31st. One analyst has rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the company. Adient has an average rating of “Hold” and an average target price of $24.52.\nAdient Profile\nAdient plc designs, manufactures, and markets a range of seating systems and components for passenger cars, commercial vehicles, and light trucks. It operates through three segments: Seating, Seat Structures and Mechanisms (SS&M), and Interiors. The Seating segment produces seat systems for automotive and other mobility applications, as well as various components of seat systems, including foams, trims, and fabrics. Receive News & Ratings for Adient analysts' ratings for Adient and related companies daily email newsletter . «",
        "highlightText": "",
        "highlightTitle": "",
        "language": "english",
        "external_links": [
          "https://www.sec.gov/Archives/edgar/data/1439140/000112760220010287/xslF345X03/form4.xml",
          "https://marketbeat.com/stocks/NYSE/ADNT/sec-filings/",
          "https://www.marketbeat.com/stocks/NYSE/ADNT/sec-filings",
          "https://www.sec.gov/Archives/edgar/data/1670541/000112760220011086/xslF345X03/form4.xml",
          "https://sec.gov/Archives/edgar/data/1439140/000112760220010287/xslF345X03/form4.xml",
          "https://www.marketbeat.com/stocks/NYSE/ADNT/sec-filings/",
          "https://marketbeat.com/newsletter/default.aspx",
          "https://www.marketbeat.com/newsletter/default.aspx",
          "https://sec.gov/Archives/edgar/data/1670541/000112760220011086/xslF345X03/form4.xml"
        ],
        "external_images": null,
        "entities": {
          "persons": [],
          "organizations": [
            {
              "name": "adient plc",
              "sentiment": "none"
            },
            {
              "name": "nyse",
              "sentiment": "none"
            },
            {
              "name": "marshall wace llp",
              "sentiment": "none"
            },
            {
              "name": "securities and exchange commission",
              "sentiment": "none"
            },
            {
              "name": "sec",
              "sentiment": "none"
            },
            {
              "name": "tower research capital llc trc",
              "sentiment": "none"
            },
            {
              "name": "pendal group ltd",
              "sentiment": "none"
            },
            {
              "name": "dekabank deutsche girozentrale",
              "sentiment": "none"
            },
            {
              "name": "cwm llc",
              "sentiment": "none"
            }
          ],
          "locations": [
            {
              "name": "adient",
              "sentiment": "none"
            }
          ]
        },
        "rating": null,
        "crawled": "2020-03-22T17:07:41.015+02:00"
      }
    ]
}